Clinical Trial Update: A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia [Phase 2]

View source ↗

Summary

A Phase 2 dose-escalation study of once-weekly TransCon CNP in prepubertal children with achondroplasia has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• TransCon CNP (C-type natriuretic peptide prodrug)

Snippet

Sponsor: Ascendis Pharma A/S | Conditions: Achondroplasia | Phase 2 | Status: COMPLETED | Results posted: 2024-03-07